HUTCHMED closes KRAS-EGFR license to GSK outside China
Question
HUTCHMED closes KRAS-EGFR license to GSK outside China
Direct answer
The $110 million upfront payment and ex-China rights transfer shift near-term cash and pipeline optionality for HCM, while GSK takes development risk on HMPL-A830. — bullish pressure on HCM via pipeline monetization via a $110 million upfront license payment.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-21
- Published
- 2026-10-21
- Revision
- 1 · 2026-10-21
Cite as: Market Ontology, “HUTCHMED closes KRAS-EGFR license to GSK outside China”, revision 1, evidence through 2026-10-21. https://marketontology.com/catalysts/2026-10-21/hutchmed-closes-kras-egfr-license-to-gsk-outside-china-9a9840
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| HCM | ▲Bull | 1–4 weeks | pipeline monetization via a $110 million upfront license payment | 83 |
HUTCHMED closes KRAS-EGFR license to GSK outside China
The $110 million upfront payment and ex-China rights transfer shift near-term cash and pipeline optionality for HCM, while GSK takes development risk on HMPL-A830. — bullish pressure on HCM via pipeline monetization via a $110 million upfront license payment.
HUTCHMED will receive $110 million upfront and GSK gets worldwide rights excluding Greater China and Taiwan.
- SourceHUTCHMED will receive $110 million upfront and GSK gets worldwide rights excluding Greater China and Taiwan.
- TransmissionThe $110 million upfront payment and ex-China rights transfer shift near-term cash and pipeline optionality for HCM, while GSK takes development risk on HMPL-A830.
- SummaryThe deal is now closed. GSK gets ex-China rights. HUTCHMED gets $110 million upfront.
- HCMDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Sector rotation or peer guidance may override single-name reaction
- HCM closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- HCM price vs. pre-event level
- HCM volume vs. 20-day average
- Sector ETF read-through
- Options implied volatility crush
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China · Polygon News · 2026-10-21
Related catalysts
- 2026-10-21HUTCHMED closed a KRAS-EGFR license with GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closed KRAS-EGFR therapy license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closes KRAS-EGFR license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closes KRAS-EGFR conjugate license to GSK outside ChinaGSK HCM
- 2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.